The launch of USAID’s Diversifying Asia’s Pharmaceutical Supply Chain project was attended by U.S. Ambassador to Uzbekistan Jonathan Henick and representatives of the country’s Ministry of Health and Agency for Development of the Pharmaceutical Industry.
Running for two years and costing US $2.5 million, the project aims to strengthen local pharmaceutical regulation, enhance local technology and workforce skills, and attract investment in the industry. It will also ensure that medicines produced in Uzbekistan meet both national and international quality standards.
Speaking at the launch, Henick stated, “Through our partnership, we will improve the health of the people of Uzbekistan while also improving the strength and responsiveness of the public and private pharmaceutical sectors. By aligning with global standards, we not only protect patients but also boost trust in local medicines, pharmaceutical companies, pharmacists, and the healthcare system as a whole.”
A key objective of the project is promoting domestic production of medicines to boost the sector’s contribution to the nation’s economic growth.
Despite being Central Asia’s largest pharmaceutical supplier, with over 220 private manufacturers, Uzbekistan still relies heavily on imported medicines and raw materials. To address this issue, the Government of Uzbekistan offers various means of support and incentives for local manufacturers including import substitution and robust quality control regulations.
Uzbekistan currently produces around 45% of the country’s medicines, a figure which the government aims to increase to 80% by 2026.
